Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
lunes, octubre 26
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Axonex AI Group Ltd
AXNX
NASDAQ
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$1.01
-0.12
-10.62%
Últ. Act.: Oct 23, 4:51 PM
Get Report
Panorámica general
Noticias
Previsión de beneficios
Precios objetivo
Finanzas
Sentimiento
Propiedad
Comparar
Informe de acciones
División de acciones:
Se espera que Axonex AI Group Ltd se divida Thursday, October 22, 2026 con una proporción de 2:5
Axonex AI Group Financials
Axonex AI Group (AXNX) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Axonics Q3 Sales $116.20M Beat $113.50M Estimate; EPS $0.00 Vs $0.08 YoY
Axonics (NASDAQ:AXNX) reported quarterly sales of $116.20 million which beat the analyst consensus estimate of $113.50 million by 2.38 percent. This is a 24.81 percent increase over sales of $93.10 million the same
Benzinga Newsdesk
Axonics Shares Fall Despite Australia's Approval for R20 SNM Device
Axonics, Inc. (NASDAQ: AXNX) has received regulatory approval from the Therapeutic Goods Administration to market its R20 rechargeable sacral neuromodulation (SNM) system in Australia.
Zacks
PRO
Axonics Q1 EPS $(0.38) Misses $(0.08) Estimate, Sales $91.41M Beat $89.59M Estimate
Axonics (NASDAQ:AXNX) reported quarterly losses of $(0.38) per share which missed the analyst consensus estimate of $(0.08) by 375 percent. This is a 100 percent decrease over losses of $(0.19) per share from the same
Benzinga Newsdesk
Axonics Q4 EPS $0.13 Beats $0.06 Estimate, Sales $109.73M Beat $107.33M Estimate
Axonics (NASDAQ:AXNX) reported quarterly earnings of $0.13 per share which beat the analyst consensus estimate of $0.06 by 116.67 percent. This is a 1200 percent increase over earnings of $0.01 per share from the same
Happy Mohamed
Why Medical Devices Giant Boston Scientific Shares Are Rising Today
Boston Scientific shares surge in premarket trading following strong Q4 results, beating revenue estimates, amid positive outlook for 2024.
Nabaparna Bhattacharya
Why Is Bladder Disorder Focused Axonics Stock Trading Higher Today?
Boston Scientific Corporation (NYSE: BSX) has agreed to acquire Axonics Inc (NASDAQ: AXNX) for $7
Vandana Singh
